Maintenance phase in Wigobi

During demanding night shifts in internal medicine departments, healthcare professionals often experience moments of deep awareness. The constant engagement with clinical data, laboratory tests, and imaging studies can obscure the patient behind the numbers, turning the work into a series of technical tasks to be completed. In response, a profound sense of emptiness and disconnection from the original purpose for which the profession was chosen may develop, beyond the natural physical fatigue of long shifts.

This experience, shared quietly by too many doctors, is at the heart of the burnout phenomenon. We enter the medical field with noble ideals, a strong desire to heal, comfort, and be there for others in their most difficult moments. However, the demanding clinical reality – bureaucratic overload, financial pressure, endless working hours, and constant exposure to human suffering – gradually erodes these ideals. This dissonance, between the desire to provide personal and empathetic care and the requirement to meet rigid targets and protocols, creates fertile ground for the development of cynicism, emotional exhaustion, and a sense of meaninglessness.

The consequences extend far beyond the personal feelings of the healthcare worker. A burned-out doctor struggles to establish the essential therapeutic relationship, that safe space where the patient feels truly heard. Burnout turns the human encounter, which is the essence of medicine, into a series of technical tasks. It can lead to decreased concentration, impaired judgment, and ultimately, jeopardize patient safety. We cannot afford to ignore these signals, both on a personal level and at the systemic level, as the mental health of caregivers is inextricably linked to the quality of care they provide.

Therefore, the response cannot be limited to generic advice on “time management” or “finding hobbies.” It requires a profound shift in perception. We must recognize that nurturing our mental resilience is not a luxury, but an essential tool, just like a stethoscope. It begins with setting healthy boundaries, the ability to say ‘no,’ and understanding that rest is not idleness but an active process of recovery. It continues with creating collegial support networks, safe spaces where challenges and difficulties can be shared honestly, without fear of judgment. The system has a responsibility to reduce unnecessary bureaucratic burdens and recognize that investing in the well-being of teams is a direct investment in the quality of medicine. Because at the end of the day, medicine is primarily a human journey, and in order to accompany others on their journey, we must remember to maintain our own humanity.

The maintenance phase of treatment with Semaglutide 2.4 mg (Wegovy), administered once a week, is not just another chapter in treatment; it is the essence of understanding obesity as a complex chronic disease. Patients who reach their target weight after months of effort and perseverance often experience joy mixed with familiar anxiety – the fear of weight regain, a common phenomenon among those suffering from obesity. This is where the maintenance phase comes into play, not as a passive continuation but as an active strategic intervention against what can be described as “physiological betrayal.” The human body, which does not understand health intentions, interprets weight loss as a survival threat and activates an arsenal of countermeasures: metabolism slows down, and hunger hormones like ghrelin are elevated. Ongoing treatment with Semaglutide acts as a biological anchor, a neurological regulator that normalizes the tumultuous signals from the gut and brain, stabilizing the sense of fullness and providing the physiological calm necessary for the lifestyle changes, in which the patient has invested so much effort, to become a permanent habit.

The modern perception, which is based on insights from large studies like the STEP research series, compels us as doctors to engage in an honest dialogue with patients: obesity is a relapsing disease, just like hypertension or diabetes. It is inconceivable to tell a patient whose blood pressure has stabilized with medication, “Well done, now you can stop the pills.” Stopping treatment will almost certainly lead to a return of the disease. The maintenance phase with Wegovy is the pharmacological acknowledgment of this fact. Beyond weight maintenance, which is a critical achievement in itself, we witness profound and wide-ranging benefits. Ongoing treatment not only prevents weight regain but actively continues to improve patients’ cardiometabolic health. We see in the clinic how lipid profiles continue to improve, blood pressure values stabilize, and waist circumference – a powerful marker of cardiovascular risk – continues to decrease. The proven safety profile of the drug in long-term use allows us to offer patients a stable and safe treatment horizon while effectively managing side effects, which often become negligible over time.

In daily clinical practice in Israel, faced with the burden of comorbidities associated with obesity, we are committed to a change in perception. The conversation in the clinic must shift from the narrow question “How much have you lost?” to the foundational question “How do we stabilize this success for the years to come?”. The maintenance phase is not a luxury; it is the scientific and practical answer to this question. It allows for recalibrating the body’s physiological set point and creates an internal environment that enables the preservation of achievements. True success in treating obesity is not measured by the low point on the scale but by the ability to create a new and stable health reality over time. In doing so, we not only reduce numbers on the monitor screen but also restore our patients’ quality of life and health – sustainably.

Wegovy: Decoding the Biological Mechanism That Changes the Rules of the Game in Weight Maintenance

At the heart of Wegovy’s (Wegovy) action lies the active ingredient Semaglutide, an engineered molecule that serves as a precise and powerful mimic of a natural hormone called GLP-1. This hormone, which our body naturally secretes in the intestines after eating, is one of the key players in the complex regulatory system of appetite, satiety, and blood sugar balance. The problem is that the natural hormone breaks down quickly. Herein lies Semaglutide’s crucial advantage: its unique structure is engineered to withstand the enzymes that break it down, granting it an exceptional “staying power” in the body. This resistance allows it to act continuously for an entire week, explaining why just one subcutaneous injection per week is sufficient to achieve its lasting effect.

The profound impact of Wegovy on body weight does not stem from a single mechanism, but from a coordinated action, almost like an orchestra, that plays across various physiological systems in the body, both in the control center of the brain and in peripheral organs:

• Recalibration of the Control Center in the Brain: Semaglutide manages to cross the blood-brain barrier and reach directly to the “control room” of energy balance in our body – areas in the hypothalamus and brainstem. There, it binds to GLP-1 receptors and begins to “re-tune” the signals. The result is a significant increase in satiety messages and a dramatic reduction in hunger signals. For the patient, this change translates to a completely different daily experience: the incessant “noise” of thoughts about food begins to fade, a deep sense of fullness appears earlier during the meal, and intense cravings, especially for high-fat and sugary foods, lose their addictive power.
• Direct Effect on the Digestive System: Alongside its action in the brain, Wegovy also acts “on the ground” – in the stomach. The drug causes a controlled slowing of gastric emptying. This means that the food we eat stays in the stomach for a longer period. This physical effect directly contributes to a physical sense of fullness that lasts for hours after the meal, naturally helping to reduce portion sizes and decrease the need for snacking between meals.
• Restoration of Metabolic Balance: Beyond its effect on appetite, Wegovy contributes to overall metabolic health through smart regulation of blood sugar levels. It operates on a “glucose-dependent” mechanism, meaning it only activates when blood sugar levels rise. In response to sugar, it encourages the pancreas to secrete insulin, while simultaneously suppressing the secretion of glucagon (a hormone that raises blood sugar levels). This dual and precise action, combined with improved sensitivity of cells to insulin, not only helps balance sugar levels but also alleviates the heavy metabolic burden that the body faces in a state of obesity.

Once significant weight loss has been achieved, the real challenge begins: maintaining it. At this stage, our body activates ancient survival mechanisms, a kind of biological “counter-response” aimed at bringing us back to the previous higher weight. The body slows down the resting metabolic rate (a phenomenon known as “adaptive thermogenesis”) and floods the system with hormones that increase hunger and reduce satiety. This is a tough battle against our own biology. Ongoing treatment with Wegovy during the maintenance phase serves as a physiological anchor and a constant counterforce. It continues to neutralize the heightened hunger signals, preserve the sense of control and satiety, thereby allowing the “new weight point” to be “set.” In fact, Wegovy not only helps maintain the achievement but also creates a new biological environment that allows the body to adapt and stabilize at a lower and healthier weight, while providing the tools to successfully cope with the powerful biological pressures pushing for weight regain.

Frequently Asked Questions about the Maintenance Phase of Wegovy

How long does the maintenance phase of Wegovy last?

The maintenance phase in Wegovy treatment does not have a predefined endpoint, as it is designed to manage a chronic medical condition. Modern medicine now understands that obesity is not a result of a lack of willpower, but a complex disease of the brain and body systems, where the internal “thermostat” of weight (the Set Point) is set too high. Similar to the treatment of hypertension or diabetes, which aim not to “cure” the disease but to maintain balanced values over time, Wegovy operates in the same way. It serves as a continuous biological intervention that helps recalibrate the signals between the brain, digestive system, and fat cells. Imagine a strong spring that is tightened and held in place. The medication is the force that keeps the spring taut; once the force is removed, the powerful biological mechanisms that drive weight gain are “released” and work to return the body to its original weight. Therefore, as long as the treatment is beneficial and well-tolerated by the patient, the common recommendation is to continue it as a long-term treatment to maintain weight loss achievements and associated health benefits.

Is the dosage fixed during the maintenance phase?

The recommended maintenance dosage of Wegovy, 2.4 mg once a week, serves as the “treatment anchor” that has been shown to be the most effective in large-scale clinical studies (the STEP research series). This dosage was chosen because it provides optimal and continuous activation (agonism) of GLP-1 receptors in the brain and body systems, thereby maintaining appetite suppression, increased satiety, and control over “food noise” in thought. It is important to understand that the body, after weight loss, is not passive; it activates a series of powerful survival mechanisms (such as slowing metabolism and increasing hunger hormones) aimed at regaining lost weight. Maintaining the full maintenance dosage is essential to continue resisting this biological pressure. In certain situations, when a patient is dealing with persistent side effects that hinder treatment adherence, the treating physician may consider personalizing the treatment and reducing to a lower maintenance dosage, such as 1.7 mg. This decision will be made after an in-depth discussion, weighing the balance between quality of life and tolerability against the need to maintain sufficient therapeutic efficacy. However, the therapeutic goal and evidence-based approach is to persist with the 2.4 mg dosage.

What happens if treatment with Wegovy is stopped after the maintenance phase?

Stopping treatment with Wegovy, even after achieving significant weight loss that is successfully maintained, will almost certainly lead to a gradual weight regain. It is important to emphasize that this is not evidence of weakness or personal failure, but a completely expected biological response. A landmark study in the field (STEP 4 study) clearly demonstrated this: participants who stopped active treatment and switched to a placebo regained nearly 7% of their body weight within less than a year, while those who continued treatment maintained their achievements. After stopping treatment, feelings of hunger may significantly increase. Early satiety disappears, thoughts about food return frequently, and the ability to control portions and food choices decreases significantly. In fact, stopping treatment is like removing glasses from a person who needs them to see; the underlying problem still exists, and the tool that enabled its management has been removed. The body returns to its previous physiological state, which encourages fat storage.

Is there a need for lifestyle changes during the maintenance phase?

Absolutely, and critically so. Wegovy should not be viewed as a “magic solution,” but as a powerful biological aid that has opened a unique window of opportunity. The medication calms the biological “storm” of hunger and cravings, allowing the patient the mental and physical resources needed to build and establish new, sustainable lifestyle habits. During the maintenance phase, the focus shifts from active weight loss to establishing and maintaining. This is the time to make physical activity an integral part of the routine, not with the goal of “burning calories,” but to build quality muscle mass – the body’s metabolic “engine.” This is the time to learn to nourish the body with a diet rich in protein, vegetables, and fiber, which supports satiety and health. The medication and lifestyle work in synergy: the drug manages internal physiology, while the new habits manage the external environment and behavior. The combination of the two is the key to long-term success.

Can the frequency of injections be reduced during the maintenance phase?

The answer is no. The weekly injection regimen of Wegovy is not arbitrary, but based on the chemical structure and elimination rate of the drug from the body (its pharmacokinetic profile). Semaglutide, the active ingredient, has a long half-life of about seven days.

The implication is that a weekly injection ensures a stable and constant level of the medication in the bloodstream (a condition known as “Steady State”). This stable level is essential for consistent and prolonged therapeutic effects. This can be likened to watering a delicate plant: it needs a constant supply of water every week to thrive. Massive watering once a month will not help and may even harm. Similarly, spacing out injections, for example to once every two weeks, will create sharp fluctuations in medication levels. In the second week, the medication level will drop below the threshold of effectiveness, allowing intense feelings of hunger and cravings to return in full force. This situation will significantly hinder the ability to maintain weight, turning every week into a renewed struggle and jeopardizing all treatment progress. Adhering to the weekly protocol is a fundamental pillar of treatment success.

Maintenance Phase with Wegovy: From Weight Loss Coaching to Metabolic Preservation Science

Transitioning from Kilogram Hunting to Health Architecture: Medical Monitoring as a Strategic Tool

Reaching the maintenance dose of 2.4 mg Wegovy is not the finish line, but a strategic turning point in the treatment journey. The initial goal, weight loss, gives way to a more complex and delicate challenge: stabilizing the new weight set point and making it the body’s permanent physiological reality. This phase requires a proactive partnership with the treating physician, as periodic meetings shift from reporting numbers on the scale to in-depth dialogue about the body’s new state. Measurements expand beyond weight and BMI to body composition analysis, aiming to ensure that weight loss does not come at the expense of essential muscle mass. This is the time to reap the metabolic rewards: the beneficial effects on comorbidities are fully examined, and the doctor can begin the exciting process of “De-prescribing” – a controlled reduction or even cessation of long-standing medications for hypertension, diabetes, or blood lipids. Every medication that is tapered off is a resounding testament to overall treatment success and the new health that has been built.

The Quiet Struggle Against Biological Memory: The Importance of Persistent Pharmacological Adherence

Adherence to the weekly injection during the maintenance phase is the biochemical shield that preserves achievements. It ensures a constant and stable presence of the medication in the system (steady-state), serving as a continuous counterweight to the powerful physiological forces of the body that push it to return to its previous higher weight. The challenge here is less physical and more psychological. After months of effort and reaching the goal, a natural temptation arises to “let go” a little, and a sense of security may lead to erosion of the treatment routine, a phenomenon known as “success fatigue.” It is important to internalize that Wegovy does not “cure” the tendency to gain weight, but actively manages it. Skipping doses or stopping opens the door again to neuro-hormonal signals that encourage eating and fat storage. Therefore, adhering to the injection is not a technical task, but a strategic and daily act of defense over the new health territory that has been conquered with great effort.

Rebuilding the Body: The Synergy Between Medication and Established Lifestyle

The pharmacological treatment during the maintenance phase creates a biological breathing space, where the body can “learn” and adapt to the lower weight set point. But the medication cannot do this alone; it creates the optimal conditions for the success of lifestyle changes, which now take on a central and permanent role. Nutrition undergoes transformation: the focus shifts from a caloric deficit aimed at weight loss to a balanced energy intake aimed at maintenance. The emphasis is on food quality: consuming high-quality protein for building and preserving muscle tissue, and essential nutrients that support metabolic health. Concurrently, the role of physical activity is amplified and evolves. It is no longer just a tool for burning calories, but becomes the primary tool for sculpting the new body. Resistance training, in particular, is essential for building muscle mass, which serves as an active metabolic “engine” that burns energy even at rest and improves insulin sensitivity – two critical lines of defense against future weight gain.

Fine-Tuning for Quality of Life: Dynamic Management of Side Effects and Long-Term Safety

Living with Wegovy in the long term requires ongoing dialogue with the body and a strong therapeutic alliance with the medical team. The side effect profile may change: the intense gastrointestinal effects that characterized the early stages tend to moderate, but sometimes subtle and persistent effects may arise that require attention. Managing them is not passive but requires “fine-tuning” of habits. Sometimes, small changes in timing or meal composition can make a significant difference in how one feels. Continuous medical monitoring is not just a matter of routine, but a proactive safety net. It allows for early detection of any changes and monitoring of rare risks, according to the most stringent requirements. Open and honest communication with the doctor about any new sensations or phenomena is key to ensuring a safe, effective treatment journey that allows for maximum quality of life alongside impressive health achievements.

Weight Maintenance Challenge: In-Depth Clinical Analysis of Wegovy vs. GLP-1 Alternatives for the Maintenance Phase

In the clinic, we encounter many patients who, after six months of treatment and combined effort, have managed to shed a significant percentage of their body weight. The sense of achievement in the clinic is tangible, but now we face the real challenge, familiar to every clinician treating obesity: the transition from the active weight loss phase to the long-term maintenance phase. This is a critical crossroads, where the goal is no longer to “lose” but to “maintain” – to prevent the phenomenon of weight regain, the powerful biological tendency of the body to return to its previous weight. Choosing the right pharmacological treatment for this phase is not a technical decision but rather the construction of a sustainable plan tailored to the patient’s lifestyle. The following table analyzes in depth the leading options from the GLP-1 family, focusing on the essential parameters for chronic success.

The data in the table highlight a significant regulatory and clinical point: among all options, only Wegovy and Saxenda hold official indications and insurance coverage (subject to criteria) for chronic obesity treatment. This is not merely a semantic distinction; it reflects the existence of a substantial body of research that has demonstrated their efficacy and safety specifically for this purpose – long-term weight maintenance.

Now, the choice for patients is narrowed down to two proven alternatives. Here, the human factor comes into play – the ability to adhere to treatment over months and years. The pharmacokinetic and practical advantage of Wegovy is clearly evident. A treatment regimen of one weekly injection integrates more naturally into modern lifestyles, reduces daily engagement with the disease, and decreases the risk of burnout and “treatment fatigue.” In contrast, the need for daily injections with Saxenda, despite its efficacy, presents a daily hurdle that can, as we see in clinical practice, lead to a gradual decline in adherence and ultimately to treatment cessation and weight regain.

And what about Ozempic and Rybelsus? Their use for weight management in non-diabetic individuals is considered “Off-Label.” As clinicians, we must rely on evidence-based medicine. These medications have not been specifically studied at their approved doses for weight maintenance in this population. Therefore, choosing them not only deviates from the indication and insurance coverage but also represents a departure from optimal clinical practice. When the goal is to provide the patient with the best chance of maintaining their achievements, the most rational approach is to select a treatment that has been designed, researched, and approved specifically for this purpose. In this context, Wegovy, with its dedicated maintenance dose of 2.4 mg, serves as the cornerstone of pharmacological treatment for weight maintenance.

Strategic Management of the Maintenance Phase in Wegovy Treatment

Reaching the target weight is not the finish line in the battle against obesity, but rather the most critical turning point. We must understand that obesity is a chronic and insidious disease, equipped with powerful defense mechanisms. After significant weight loss, the body does not celebrate the achievement; it goes into defense mode. It interprets the loss of fat mass as an existential threat and activates an arsenal of counter-regulatory mechanisms to restore the status quo. The resting metabolic rate drops (a phenomenon known as thermogenic adaptation), and the hormonal system undergoes recalibration – hunger hormones surge while satiety hormones are suppressed. This is not a psychological battle of willpower, but a stubborn biological fight. The maintenance phase in Wegovy treatment is not a period of rest, but a stage of active fortification and proactive management of this metabolic battlefield.

At this stage, the role of Wegovy (semaglutide) changes significantly. It ceases to be the primary driving force for weight loss and becomes the biological anchor stabilizing the new weight set point achieved with great effort. Continued treatment is essential to provide a constant and continuous signal to the central nervous system. When the drug acts as a GLP-1 receptor agonist, it effectively manages a constant dialogue with the brain on two levels: it calms the physical, homeostatic hunger originating from the hypothalamus, while simultaneously diminishing the intensity of cravings and food desires stemming from the hedonic reward system. For the patient, the result is not only a sense of physical fullness but a profound experience of “metabolic calm.” That incessant “noise” of thoughts about food, the constant internal struggle, dissipates. This calm is the fertile ground that allows patients to adopt and internalize healthy lifestyle habits, not out of struggle and resistance, but from a relaxed and conscious choice.

Long-term success in managing obesity relies on a threefold alliance: pharmacological treatment, behavioral change, and environmental support. Wegovy provides the biochemical scaffolding, the safety net that neutralizes the body’s powerful physiological drive to regain lost weight. On this stable foundation, the therapeutic framework – which includes continuous medical monitoring, guidance from a clinical dietitian, and a thoughtful integration of physical activity – enables the patient to rebuild their lifestyle. The maintenance phase should be viewed as a dynamic process of learning and adaptation, similar to how we manage other chronic diseases like hypertension or diabetes. Discontinuing treatment is akin to removing the dam in front of a raging river. Ongoing treatment with Wegovy is not a “crutch,” but the scientific basis that allows for the maintenance of stable metabolic health and the prevention of disease recurrence. This is the modern standard of care, recognizing the biological complexity of obesity and offering a sustainable solution.

Wegovy Maintenance Safety Profile and Clinical Management

The maintenance phase of treatment with Wegovy is not a static endpoint, but rather a new and dynamic chapter in the treatment journey. After the patient has reached the target dose and achieved the initial weight loss goals, the focus shifts from active weight loss to maintaining achievements and building long-term metabolic resilience. This phase relies on a well-established safety profile, as evidenced by comprehensive clinical studies. However, ongoing success depends on informed and proactive management of side effects, which are largely a predictable outcome of the drug’s unique mechanism of action. A deep understanding of these effects, particularly those related to the gastrointestinal system and resulting from delayed gastric emptying, allows for an open and ongoing therapeutic dialogue. This partnership between the patient and the medical team is key to a delicate balance between maximizing treatment efficacy and maintaining a high quality of life.

Common Side Effects: Understanding the Mechanism and Proactive Management Approaches

• Gastrointestinal symptoms (nausea, vomiting, changes in bowel movements): This is the primary group of side effects, directly related to the central mechanism that induces satiety – the slowing of gastric emptying.
  • Nausea: This sensation, which tends to diminish over time, can be effectively managed through behavioral adjustments. The key is to transition to smaller, more frequent meals that prevent overload on a slowly emptying stomach. Attention should be paid to slow and thorough chewing, and there should be a conscious avoidance of high-fat, fried, or strongly aromatic foods that may trigger symptoms. Another critical skill is recognizing early satiety signals and stopping eating as soon as they appear, rather than waiting for a feeling of fullness. Drinking clear fluids between meals, rather than during them, also contributes to relief.
  • Vomiting: In cases of recurrent vomiting, the immediate concern is preventing dehydration and electrolyte imbalance. Medical attention should be sought for evaluation, supportive treatment if necessary, and consideration of a temporary adjustment of the treatment.
  • Diarrhea or constipation: These changes in bowel activity require focused dietary adjustments. In the case of constipation, the diet should be gradually enriched with dietary fibers from diverse sources (vegetables, whole fruits, legumes, whole grains), ensuring adequate water intake throughout the day, and incorporating regular physical activity to stimulate bowel function. In the case of diarrhea, the emphasis is on maintaining hydration (water, herbal tea, clear soups) and avoiding foods that may exacerbate the condition.
• Abdominal pain and reflux (heartburn): Mild abdominal discomfort or a sensation of heartburn may occur. Heartburn can be treated with antacid preparations and ensuring a time gap between meals and lying down. However, patients should be instructed to report immediately any sharp, sudden, persistent abdominal pain or pain radiating to the back, especially if accompanied by fever or vomiting, to rule out complications.
• Fatigue and exhaustion: Feelings of fatigue may stem from the direct effects of the drug, but often reflect the body’s metabolic adaptation to a caloric deficit and weight loss. Maintaining good sleep hygiene, a balanced diet rich in essential nutrients, and periodic blood tests to rule out nutritional deficiencies can be significantly helpful.
• Headaches: These are usually mild and transient, responding well to over-the-counter pain relievers. Maintaining proper fluid balance, which becomes more challenging during weight loss, is an important preventive strategy.
• Hypoglycemia (low blood sugar): The risk of hypoglycemia in non-diabetic patients is very low. This is because the drug increases insulin secretion only in the presence of high glucose levels (glucose-dependent mechanism). In contrast, in patients with type 2 diabetes who are concurrently receiving treatment with sulfonylurea medications or insulin, the risk increases. In these cases, careful monitoring of blood sugar levels is required, and often the medical team will perform a preventive reduction in the doses of other diabetes medications upon starting treatment with Wegovy.

Contraindications, Warnings, and Special Populations Requiring Special Attention

Absolute Contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome: This is a severe contraindication (“black box warning”) arising from studies in animals that demonstrated an increased risk. Although the connection in humans has not been definitively proven, the theoretical risk necessitates complete avoidance of the drug in this population.
• Pregnancy and breastfeeding: Wegovy is prohibited during pregnancy and breastfeeding. Patients should be advised to use effective contraceptive methods and to discontinue treatment at least two months before attempting to conceive, to allow for complete elimination of the drug from the body.

Conditions Requiring Caution and Increased Monitoring:

• Kidney or liver failure: Caution should be exercised in patients with impairment of these organs, particularly in cases of severe impairment. Severe gastrointestinal side effects may lead to dehydration and acute worsening of kidney function, thus close monitoring is required.
• Pancreatitis: It is essential to instruct every patient to recognize and report immediately any suspicious symptoms: severe and persistent abdominal pain.

  In the upper abdomen, which often radiates like a belt to the back, and may be accompanied by vomiting. A history of pancreatitis is not an absolute contraindication, but requires an in-depth discussion about the risk-benefit balance.

• Biliary tract diseases: Rapid weight loss, by any means, is a known risk factor for the development of gallstones (cholelithiasis) due to changes in bile composition. One should be alert to symptoms such as intermittent pain in the upper right abdomen.

The maintenance phase is a stage of active therapeutic partnership. Regular medical follow-up is not only intended for weight measurement but also serves as an opportunity for ongoing monitoring of side effects, early identification of risks, and dynamic adjustment of the overall treatment approach. This ensures that the impressive health achievements of the treatment are safely and effectively maintained over time.

Weight Maintenance Phase with Wegovy: An In-Depth Clinical Perspective for Long-Term Treatment

The Synergy Between Pharmacological Intervention and Lifestyle Change: Moving Beyond the “Magic Solution” Concept

From a clinical perspective: One of the most challenging perceptions we encounter in the clinic is the expectation that Wegovy (semaglutide) will serve as an independent “magic solution,” eliminating the need for active involvement in the process. This perception overlooks the delicate physiological dance occurring in the body. Wegovy, as a GLP-1 receptor agonist, does not build a fortress against calories; its role is more akin to that of a conductor in our hormonal orchestra. It resonates in the brain’s control centers (the hypothalamus) and gently regulates feelings of hunger and satiety. Simultaneously, it slows gastric emptying, thereby providing a more substantial and prolonged sense of physical fullness after meals. This combined action creates a precious physiological window of opportunity: the incessant biological “noise” pushing for eating diminishes. This relative quiet allows the patient, perhaps for the first time in years, to choose more consciously and deliberately, to implement dietary changes and persist in them. However, if we continue to inundate the system with energy-dense and nutritionally poor food, ultimately, the caloric assault will overwhelm the pharmacological protection. This will lead to weight stagnation or, worse, a rebound increase. The success of treatment in the maintenance phase is not measured solely by adherence to the injection but by the ability to leverage pharmacological support to build and reinforce healthy lifestyle habits that will accompany the patient for years.

The Rationale for Long-Term Treatment: A Stubborn Fight Against Metabolic Adaptation

From a clinical perspective: The discussion about the duration of treatment with Wegovy touches on the core of modern understanding of obesity as a chronic, complex, and persistent disease. For years, society viewed obesity as a failure of willpower, but science tells a different story. After significant weight loss, the body does not celebrate the achievement; it recognizes a state of emergency, a kind of potential “hunger,” and activates ancient and powerful survival mechanisms. This physiological counter-response, known as “metabolic adaptation,” is a formidable adversary: resting energy expenditure drops (the body becomes “more economical”), leptin levels (the satiety hormone) decrease, and ghrelin levels (the hunger hormone) surge. The result is a daily struggle, almost impossible, against increased hunger and a slower metabolism. Stopping treatment with Wegovy is akin to lowering the shield and exposing the patient to the full force of this biological assault. The drug does not “cure” the genetic and physiological predisposition to obesity; it serves as an active and ongoing therapeutic tool that neutralizes some of the distress signals the body sends. The STEP 4 study, a landmark in the field, clearly demonstrated this: patients who continued treatment maintained the impressive weight loss. In contrast, those who were switched to the placebo group experienced a rapid regain of most of the lost weight. The maintenance phase is not a period of passive rest; it is the most crucial active treatment phase, allowing for the preservation of results against the tremendous biological pressures of the body.

The Impact of Treatment on Reproductive Health and Fertility: Debunking Myths and Presenting the Full Picture

From a clinical perspective: A common and entirely understandable question that arises among patients of reproductive age concerns the impact of treatment on the likelihood of conception. It is important to clarify unequivocally: as of today, there is no evidence in the scientific literature indicating that semaglutide directly harms male or female fertility. The blanket recommendation to stop treatment about two months before attempting to conceive, and to avoid it during pregnancy and breastfeeding, stems from the principle of precautionary caution. This principle is a standard practice in medicine when controlled studies in these populations are not available—studies that will never be conducted for clear ethical reasons. The two-month waiting period ensures that the active ingredient is completely cleared from the system. However, the real and more important story is actually the opposite aspect: obesity itself is a significant and proven risk factor for fertility impairment. Dramatic weight loss, achieved through combined treatment, brings with it a tremendous improvement in metabolic and hormonal profiles. For women with polycystic ovary syndrome (PCOS), for example, a 5%-10% reduction in body weight can regulate the menstrual cycle, restore spontaneous ovulation, and significantly increase the chances of conception. Among men, weight loss is associated with improved sperm parameters. Therefore, instead of viewing treatment as an obstacle, it should be seen as an opportunity: for the right patients, Wegovy may actually be a factor supporting improved fertility and helping to realize the dream of starting a family.

Wegovy in Israel: The Paradigm of Chronic Treatment and the Challenge of Long-Term Weight Maintenance

The emergence of Wegovy (Semaglutide) in the therapeutic arena in Israel is not just a pharmacological milestone, but a profound shift in how we understand and address obesity. The prevailing perception, which views weight loss as the ultimate goal, is giving way to the understanding that obesity is a chronic, complex disease with deep physiological roots. Therefore, the impressive success in the early stages of treatment is not the finish line, but rather the starting gun for the truly critical and challenging phase: the maintenance phase. The inclusion of the drug in the health services basket for patients who meet clear criteria (a Body Mass Index (BMI) of 30 or higher, or 27 or higher with at least one obesity-related risk factor) provides the essential systemic anchor for long-term management. This recognition allows both medical teams and patients to confront the real challenge: dealing with the powerful biological survival mechanisms of the body that fight to regain lost weight.

The main difficulty in weight maintenance arises from the body’s relentless struggle to maintain metabolic homeostasis. After weight loss, the body activates a series of sophisticated compensatory mechanisms, as if it has an internal “thermostat” set to the previous higher weight (Set Point), and it will do everything to return to it. These mechanisms form a complete biological orchestra: resting metabolic rate slows down, levels of the hunger hormone ghrelin surge, while levels of satiety hormones, such as leptin and natural GLP-1, drop. This is where Wegovy comes into play. As a mimic of the GLP-1 hormone, it acts directly on the appetite and satiety centers in the brain, providing a pharmacological “counterweight” to that physiological response. It effectively “silences” the powerful hunger signals and regulates the urge to regain lost energy. Therefore, stopping the treatment does not free the patient but exposes them fully to their biological system that demands a return to the previous weight. This is why persistence in treatment is not “dependency,” but rather a thoughtful medical management of a chronic disease, just as one continuously treats high blood pressure or diabetes.

The success of long-term treatment with Wegovy does not rely on the drug alone, but on building a holistic and multidisciplinary treatment framework. The treating physician, whether a family doctor or an endocrinologist, serves as the navigator of the treatment: they continuously monitor metabolic indicators, dynamically adjust the dosage, manage side effects, and provide the essential support and guidance for such a long journey. Simultaneously, the role of the clinical dietitian becomes more central and vital than ever, especially in the maintenance phase. Their role extends far beyond meal planning; they become a personal coach for a healthy lifestyle. They provide tools to cope with behavioral challenges, develop strategies for relapse prevention, and help establish sustainable eating and exercise patterns. The overarching shared goal is to embed behavioral changes until they become a natural part of the patient’s identity and routine. In this way, the physiological support of the drug and the behavioral support of professional guidance combine into a single, powerful, and sustainable strategy that ensures the preservation of achievements for many years.

The Maintenance Phase in Wegovy Treatment: A Strategy for Weight Loss to Long-Term Health Management

The weight maintenance phase in Wegovy (Wegovy) treatment represents the critical transition from initial success to sustainable achievement, directly addressing the deepest biological challenge of weight loss: the body’s natural tendency to regain what it has lost. After significant weight loss, the body does not accept the new state as the default; it fights to return to the higher weight, which it “remembers” as the equilibrium point. This battle is fought on two main fronts: first, the body’s metabolic “thermostat” decreases, and the metabolic rate slows down to conserve energy. Second, a hormonal storm occurs – hunger hormones, like ghrelin, shout louder, while satiety hormones, like leptin, whisper. Wegovy, through the active ingredient Semaglutide, acts as a skilled mediator in this complex relationship. It does not fight the body but gently influences the appetite control centers in the brain (in the hypothalamus) to lower the “volume” of hunger, while simultaneously slowing gastric emptying to extend the feeling of physical fullness. This dual physiological support is what allows for the neutralization of the biological pull back to the old weight and stabilizes the achievement as a new and healthy starting point.

Wegovy does not build the house, but it certainly provides the stable scaffolding and the necessary industrial peace for its construction. The treatment opens a priceless “window of opportunity”: the powerful hunger and intrusive thoughts about food subside, creating a mental and physiological space that allows for a transition from building a temporary “dam” against hunger (diet) to creating a new “river channel” of healthy lifestyle habits. This is the time to replace the mentality of struggle and restriction, characteristic of diets, with an approach of nurturing and nourishment. Instead of diligently counting calories, the goal is to learn to listen again to the body’s signals, choose foods that nourish and provide energy, and incorporate physical activity that is not a punishment, but a celebration of the body’s capabilities. The deep understanding that obesity is a chronic disease, just like diabetes or hypertension, is the cornerstone of success. Ongoing pharmacological treatment is not a temporary “crutch” thrown away after recovery, but an essential and ongoing management tool that allows for stable control of the disease and prevents its recurrence.

If the weight loss journey is climbing a mountain, the maintenance phase is the complex navigation along the ridge line, where the view is stunning but the path requires constant attention. In this journey, the treating physician does not wait at the summit, but serves as an experienced navigator walking alongside you. The maintenance phase is not a static state of “set it and forget it”; it is a dynamic period of fine-tuning. Continuous medical monitoring allows for personalized adjustments in medication dosage, tracking improvements in health metrics (such as blood sugar and blood pressure levels), and proactively managing any side effects. But beyond the clinical data, a therapeutic partnership is formed. Open communication is the compass of treatment: sharing challenges, successes, or changes in feelings allows the doctor to offer personalized solutions and provide support at the right moments. This honest and continuous dialogue is the mechanism that transforms treatment from a series of medical instructions into a shared journey, ensuring that reaching the summit is not a fleeting event, but the beginning of a new and healthy path.

Important medical statement: The information in this article is intended for informational purposes only and does not constitute a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified physician or healthcare professional before taking medications, changing dosages, or making any health-related decisions. Do not ignore medical advice or delay seeking medical attention because of something you read on this site.